Cellular therapies clinical trial - Celgene JCAR017-BCM-003

Status:

Pending

ClinicalTrials.gov:

NCT03805789

CONDITION(S): Graft Versus Host Disease - TRIAL: Celgene JCAR017-BCM-003-The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo‑controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).

The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft‑Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)

Drug

Biological: Alpha-1 antitrypsin (AAT)Biological: Placebo

Phase

Phase 2/3

Condition

Graft Versus Host Disease (GVHD)

Keywords

Graft Versus Host Disease (GVHD) | Celgene JCAR017-BCM-003